Triple therapy is under-used in HFrEF, according to findings published in the Journal of Cardiac Failure. Finlay McAlister, MD, MSc, and colleagues examined 14,092 patients with novel HF; 54.9% had HFrEF. By 1 year after diagnosis in the HFrEF cohort, 9.5% had received no therapy; 27.5% received monotherapy, 41.6% received dual therapy, and 21.4% received triple therapy. Median times to mono-, dual- and triple-therapy in HFrEF were 1, 8, and 14 days, respectively. Patients receiving triple therapy had lower rates of clinical outcomes compared with all other therapeutic groups (adjusted HR, 0.15, for the composite of death, HF hospitalization, or HF ED visit).
